Stifel Financial Corp Has $6.91 Million Stake in Cabot Co. (NYSE:CBT)

Stifel Financial Corp lifted its holdings in shares of Cabot Co. (NYSE:CBT - Free Report) by 68.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,717 shares of the specialty chemicals company's stock after purchasing an additional 30,694 shares during the quarter. Stifel Financial Corp owned 0.14% of Cabot worth $6,914,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of CBT. R Squared Ltd bought a new stake in shares of Cabot during the fourth quarter worth $26,000. EverSource Wealth Advisors LLC raised its stake in shares of Cabot by 37.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company's stock valued at $74,000 after purchasing an additional 219 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Cabot by 10.7% in the fourth quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company's stock valued at $123,000 after purchasing an additional 130 shares in the last quarter. Manchester Capital Management LLC boosted its position in shares of Cabot by 1,685.1% during the fourth quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company's stock worth $153,000 after buying an additional 1,584 shares during the period. Finally, KBC Group NV grew its holdings in shares of Cabot by 43.1% during the fourth quarter. KBC Group NV now owns 2,046 shares of the specialty chemicals company's stock worth $187,000 after buying an additional 616 shares in the last quarter. Institutional investors own 93.18% of the company's stock.

Cabot Stock Down 0.2 %

Cabot stock opened at $79.02 on Tuesday. Cabot Co. has a twelve month low of $73.63 and a twelve month high of $117.46. The stock has a market cap of $4.28 billion, a P/E ratio of 10.49, a P/E/G ratio of 0.74 and a beta of 1.04. The company's 50-day moving average price is $81.74 and its two-hundred day moving average price is $93.34. The company has a quick ratio of 1.29, a current ratio of 2.00 and a debt-to-equity ratio of 0.72.

Cabot (NYSE:CBT - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. As a group, analysts expect that Cabot Co. will post 7.57 EPS for the current year.

Wall Street Analyst Weigh In

CBT has been the subject of a number of recent research reports. Mizuho reduced their price target on Cabot from $122.00 to $110.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their target price on shares of Cabot from $105.00 to $85.00 and set an "underweight" rating for the company in a report on Friday, February 21st. UBS Group lowered their price target on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Finally, StockNews.com upgraded shares of Cabot from a "hold" rating to a "buy" rating in a research note on Thursday, April 17th.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.